Skip to main content
SGHT
NASDAQ Industrial Applications And Services

Sight Sciences 10-Q: Q3 Revenue $24.9M, Net Loss Narrows to $6.8M, Cash $77.4M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$9.43
Mkt Cap
$533.252M
52W Low
$3.378
52W High
$10.06
52W Position info
179% above low
Off High info
6.3% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

SGHT has more than doubled off its 52-week low of $3.378 on elevated volume (2.2× avg).

Summary

Sight Sciences' Q3 10-Q confirms $24.9M revenue (+25%) and a narrowed $6.8M net loss, with $77.4M of cash against $41.0M of debt and nine-month operating burn down to $15.1M from $27.9M.


Key Events · Earnings and Guidance · SGHT

  • Q3 Revenue Up 25% to $24.9M

    Revenue rose to $24.9M from $19.9M a year ago, with Interventional Dry Eye jumping to $3.9M from $0.2M and Interventional Glaucoma up 6.7% to $21.0M.

  • Net Loss Narrows to $6.8M

    Q3 net loss was $6.8M, or $(0.12) per share, versus $8.2M and $(0.16) a year ago; nine-month loss was $24.2M versus $34.3M.

  • Cash Burn Cut, Runway Extended

    Nine-month operating cash use fell to $15.1M from $27.9M. Cash and equivalents stood at $77.4M at September 30, 2026 against $41.0M carrying value of Hercules term debt.

  • Hercules Interest-Only Period Extended

    An October 2026 fourth amendment pushed the interest-only expiration from February 1, 2027 to August 1, 2027, moving $6.1M of debt back to long-term; maturity remains July 1, 2028.


Analysis · SGHT · Industrial Applications And Services

The headline Q3 beat and raised guidance already hit the tape via this morning's 8-K, so the incremental news here is the balance sheet and cash trajectory. Nine-month operating cash burn fell to $15.1M from $27.9M a year ago, and with $77.4M of cash against $41.0M of term debt the company has funded runway well past the next twelve months — the going-concern question that hangs over a loss-making medtech is off the table for now. The October amendment pushing the interest-only period to August 1, 2027 removes near-term principal payments. The open risk is the Alcon appeal: $55.4M of awarded damages plus a 10% ongoing royalty ride on the Federal Circuit outcome and one remaining patent reexamination.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SGHT was trading at $9.43 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $533.3M. The 52-week trading range was $3.38 to $10.06. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SGHT - Latest Insights

SGHT
Nov 04, 2026, 4:12 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.43
Real-time Price: $9.76 info
Change: +$0.330 (+3%) info
Market Cap: $537.659M info
SGHT
Nov 04, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $9.43
Real-time Price: $9.76 info
Change: +$0.330 (+3%) info
Market Cap: $537.659M info
SGHT
Aug 19, 2026, 7:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $8.04
Real-time Price: $9.76 info
Change: +$1.72 (+21%) info
Market Cap: $537.659M info
SGHT
Aug 05, 2026, 4:49 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $5.86
Real-time Price: $9.76 info
Change: +$3.90 (+67%) info
Market Cap: $537.659M info
SGHT
Aug 05, 2026, 4:21 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.25
Real-time Price: $9.76 info
Change: +$4.51 (+86%) info
Market Cap: $537.659M info